Kiniksa Pharmaceuticals International, plcKNSAEarnings & Financial Report
Kiniksa Pharmaceuticals International plc is a global biopharmaceutical firm focused on discovering, developing and commercializing targeted therapies for patients with unmet medical needs, primarily in autoimmune, inflammatory and rare disease segments. It operates across major markets including North America, Europe and Asia, advancing a pipeline of clinical-stage and approved treatment candidates.
KNSA Q4 FY2025 Key Financial Metrics
Revenue
$202.1M
Gross Profit
$181.2M
Operating Profit
$19.8M
Net Profit
$14.2M
Gross Margin
89.6%
Operating Margin
9.8%
Net Margin
7.0%
YoY Growth
65.0%
EPS
$0.18
Kiniksa Pharmaceuticals International, plc Q4 FY2025 Financial Summary
Kiniksa Pharmaceuticals International, plc reported revenue of $202.1M (up 65.0% YoY) for Q4 FY2025, with a net profit of $14.2M (up 259.8% YoY) (7.0% margin). Cost of goods sold was $20.9M, operating expenses totaled $161.4M.
Key Financial Metrics
| Total Revenue | $202.1M |
|---|---|
| Net Profit | $14.2M |
| Gross Margin | 89.6% |
| Operating Margin | 9.8% |
| Report Period | Q4 FY2025 |
Kiniksa Pharmaceuticals International, plc Annual Revenue by Year
Kiniksa Pharmaceuticals International, plc annual revenue history includes year-by-year totals (for example, 2025 revenue was $677.6M).
Kiniksa Pharmaceuticals International, plc Quarterly Revenue & Net Profit History
Kiniksa Pharmaceuticals International, plc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $202.1M | +65.0% | $14.2M | 7.0% |
| Q3 FY2025 | $180.9M | +61.2% | $18.4M | 10.2% |
| Q2 FY2025 | $156.8M | +44.3% | $17.8M | 11.4% |
| Q1 FY2025 | $137.8M | +72.5% | $8.5M | 6.2% |
| Q4 FY2024 | $122.5M | +46.9% | $-8.9M | -7.3% |
| Q3 FY2024 | $112.2M | +67.4% | $-12.7M | -11.3% |
| Q2 FY2024 | $108.6M | +52.0% | $-3.9M | -3.6% |
| Q1 FY2024 | $79.9M | +65.2% | $-17.7M | -22.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $79.9M | $108.6M | $112.2M | $122.5M | $137.8M | $156.8M | $180.9M | $202.1M |
| YoY Growth | 65.2% | 52.0% | 67.4% | 46.9% | 72.5% | 44.3% | 61.2% | 65.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $519.7M | $542.4M | $555.3M | $580.6M | $599.3M | $661.1M | $712.3M | $763.6M |
| Liabilities | $87.8M | $107.3M | $118.3M | $142.1M | $141.8M | $166.1M | $176.9M | $196.0M |
| Equity | $431.9M | $435.1M | $437.0M | $438.4M | $457.5M | $495.0M | $535.4M | $567.6M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $4.0M | $5.2M | $-2.2M | $18.8M | $22.3M | $28.1M | $33.7M | $53.9M |